Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, BT-001 was able…
Dietary Supplements Market to Reach USD 63.93 Billion by 2031, Growing at 7.4% CAGR
Westford, USA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Dietary Supplements Market will attain a value of USD 283 billion by 2031, with a CAGR of 7.4%…
Healthcare Analytics Market Forecast to Grow at 25.6% CAGR from 2024 to 2031
Westford, USA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Healthcare Analytics Market will attain the value of USD 212.3 Billion by 2031, with a CAGR of 25.6% during…
CORRECTION: Invesco Ltd: Form 8.3
FORM 8.3 CORRECTION TO AN OPENING POSITION DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) Amendment – this form…
Mulvihill Capital Management Inc. Announces Ratios for Merger of S Split Corp. into Premium Global Income Split Corp.
TORONTO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (TSX: SBN, SBN.PR.A, PGIC and PGIC.PR.A) Mulvihill Capital Management Inc., the manager of S Split Corp. (“SBN”), announced that, following approval by holders…
Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase I/IIa dans les tumeurs solides résistantes
Les premières données cliniques présentées à l’ESMO 2024 montrent que BT-001 induit une diminution de la taille des tumeurs chez des patients en échec thérapeutique Chez un patient atteint d’un…
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM-…
Form 8.3 – [KEYWORDS STUDIOS PLC – 12 09 2024]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Form 8.3 – [ECKOH PLC – 12 09 2024]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Bitfarms Enters into 10,000 Miner Hosting Agreement with Stronghold Digital Mining
- Agreement to support 2.2 EH/s with energization expected in October, two months ahead of schedule - - Company reiterates 2024 & 2025 guidance of 21 EH/s & 35+ EH/s,…